More developments on the health front emerged Tuesday, of special interest to those with diabetes or loved ones attempting to look after them.
Los Angeles-based Decision Diagnostics Corp. (OTC:DECN), a diabetes-focused bio-technology R&D firm, announced Tuesday that its Korean R&D group, with DECN CEO Keith Berman and his Stoney Fork new products experts, have designed a method and determined meter specifics for the adding of the company's TBG technology to the upcoming GenChoice test strip now in Food and Drug Administration (FDA) 510K review.
Development of this newer version of the already new GenChoice test strip will be six months from the engineering feasibility to the filing of the 510K with the FDA.
DECN stock climbed 29-100ths of a cent, or 6.4%, to 4.79 cents, early Tuesday afternoon on volume of 183,000
